Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1574832
PUBLISHER: Grand View Research | PRODUCT CODE: 1574832
U.S. General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug, By Route of Administration, By End-use, By Application, By Country, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 70 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. General Anesthesia Drugs Market Growth & Trends:
The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.8% from 2024 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.
Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.
Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.
U.S. General Anesthesia Drugs Market Report Highlights:
- Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.4% in 2023 and is also expected to grow at the fastest CAGR of 3.4% during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
- Based on route of administration, the intravenous segment held the largest revenue share of 63.1% in 2023 and is also expected to grow at the fastest CAGR of 3.0% during the forecast period
- Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
- Based on end use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.2% in 2023. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.
Product Code: GVR-4-68040-451-8
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Drug
- 1.2.2. Route of Administration
- 1.2.3. End Use
- 1.2.4. Application
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Drug Outlook
- 2.2.2. Route of Administration
- 2.2.3. End Use
- 2.2.4. Application
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing Volume Of Surgical Procedures
- 3.2.1.2. Advancements In Anesthesia Technology
- 3.2.1.3. Regulatory Developments
- 3.2.2. Market restraint analysis
- 3.2.2.1. Regulatory and Compliance Challenges
- 3.2.2.2. Adverse Effects and Safety Concerns
- 3.2.1. Market driver analysis
- 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.1. Industry Analysis - Porter's
Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis
- 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
- 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
- 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
- 4.4. Sevoflurane
- 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Propofol
- 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Dexmedetomidine
- 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Remifentanil
- 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Desflurane
- 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Midazolam
- 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Others
- 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis
- 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
- 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
- 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
- 5.4. Intravenous
- 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Inhaled
- 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis
- 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
- 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
- 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
- 6.4. Hospitals
- 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Ambulatory Surgical Centers
- 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Others
- 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis
- 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
- 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
- 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
- 7.4. Heart Surgeries
- 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Cancer
- 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. General Surgery
- 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7. Knee and hip replacements
- 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
- 7.8. Other
- 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.2.1. U.S.
- 8.2.1.1. Key country dynamics
- 8.2.1.2. Regulatory framework/ reimbursement structure
- 8.2.1.3. Competitive scenario
- 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.2.1. U.S.
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Vendor Landscape
- 9.2.1. List of key distributors and channel partners
- 9.2.2. Key company market share analysis, 2023
- 9.2.3. Baxter International Inc.
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Drug benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. AstraZeneca
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Drug benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. AbbVie Inc.
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Drug benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. B. Braun Melsungen AG
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Drug benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Fresenius SE & Co. KgaA
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Drug benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Pfizer
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Drug benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Hospira Inc.
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Drug benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. Aspen Pharmacare Holdings Limited
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Drug benchmarking
- 9.2.10.4. Strategic initiatives
- 9.2.11. Hikama Pharmaceuticals plc
- 9.2.11.1. Company overview
- 9.2.11.2. Financial performance
- 9.2.11.3. Drug benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Abbott Laboratories
- 9.2.12.1. Company overview
- 9.2.12.2. Financial performance
- 9.2.12.3. Drug benchmarking
- 9.2.12.4. Strategic initiatives
Product Code: GVR-4-68040-451-8
List of Tables
- Table 1 List Of Abbreviation
- Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
- Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
- Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
- Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Primary interviews in North America
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
- Fig. 10 Colorectal Surgery Competitive Insights
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
- Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
- Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
- Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
- Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
- Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
- Fig. 19 Propofol market estimates and forecast, 2018 - 2030
- Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
- Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
- Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
- Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
- Fig. 24 Others market estimates and forecast, 2018 - 2030
- Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
- Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
- Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
- Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
- Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
- Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
- Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
- Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
- Fig. 33 Others market estimates and forecast, 2018 - 2030
- Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
- Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
- Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
- Fig. 37 Cancer market estimates and forecast, 2018 - 2030
- Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
- Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
- Fig. 40 Other market estimates and forecast, 2018 - 2030
- Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.